| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Olga Valverde, Marta Rodríguez-Ária. Modulation of 3,4-methylenedioxymethamphetamine effects by endocannabinoid system. Current pharmaceutical design. vol 19. issue 40. 2014-08-29. PMID:23574444. |
cannabis derivatives act on endocannabinoid system. |
2014-08-29 |
2023-08-12 |
human |
| Olga Valverde, Marta Rodríguez-Ária. Modulation of 3,4-methylenedioxymethamphetamine effects by endocannabinoid system. Current pharmaceutical design. vol 19. issue 40. 2014-08-29. PMID:23574444. |
this paper represents a brief overview of the pharmacological interaction between mdma and cannabis derivatives acting in the endocannabinoid system. |
2014-08-29 |
2023-08-12 |
human |
| Marta Solinas, Paola Massi, Valentina Cinquina, Marta Valenti, Daniele Bolognini, Marzia Gariboldi, Elena Monti, Tiziana Rubino, Daniela Parolar. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PloS one. vol 8. issue 10. 2014-08-26. PMID:24204703. |
cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in u87-mg and t98g glioma cells through a multitarget effect. |
2014-08-26 |
2023-08-12 |
Not clear |
| T D M Hill, M-G Cascio, B Romano, M Duncan, R G Pertwee, C M Williams, B J Whalley, A J Hil. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. British journal of pharmacology. vol 170. issue 3. 2014-08-19. PMID:23902406. |
here, we investigate (i) the anticonvulsant profiles of cannabis-derived botanical drug substances (bdss) rich in cannabidivarin (cbdv) and containing cannabidiol (cbd) in acute in vivo seizure models and (ii) the binding of cbdv bdss and their components at cannabinoid cb1 receptors. |
2014-08-19 |
2023-08-12 |
mouse |
| Francisco Espejo-Porras, Javier Fernández-Ruiz, Roger G Pertwee, Raphael Mechoulam, Concepción Garcí. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. vol 75. 2014-08-19. PMID:23924692. |
by contrast, cannabidiol (cbd), a phytocannabinoid with a broad therapeutic profile, is generally presented as an example of a cannabinoid compound with no motor effects due to its poor affinity for the cb1 and the cb2 receptor, despite its activity at the trpv1 receptor. |
2014-08-19 |
2023-08-12 |
rat |
| Ewa Kozela, Ana Juknat, Nathali Kaushansky, Neta Rimmerman, Avraham Ben-Nun, Zvi Voge. Cannabinoids decrease the th17 inflammatory autoimmune phenotype. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23892791. |
cannabinoids, the cannabis constituents, are known to possess anti-inflammatory properties but the mechanisms involved are not understood. |
2014-08-18 |
2023-08-12 |
mouse |
| Ewa Kozela, Ana Juknat, Nathali Kaushansky, Neta Rimmerman, Avraham Ben-Nun, Zvi Voge. Cannabinoids decrease the th17 inflammatory autoimmune phenotype. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23892791. |
here we show that the main psychoactive cannabinoid, Δ-9-tetrahydrocannabinol (thc), and the main nonpsychoactive cannabinoid, cannabidiol (cbd), markedly reduce the th17 phenotype which is known to be increased in inflammatory autoimmune pathologies such as multiple sclerosis. |
2014-08-18 |
2023-08-12 |
mouse |
| Sauid Ishaq, Sanaa Ismail, Saad Ghaus, Roop-E-Zahra, Kamran Rostam. Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. Gastroenterology and hepatology from bed to bench. vol 7. issue 3. 2014-08-14. PMID:25120899. |
cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. |
2014-08-14 |
2023-08-13 |
Not clear |
| Sauid Ishaq, Sanaa Ismail, Saad Ghaus, Roop-E-Zahra, Kamran Rostam. Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. Gastroenterology and hepatology from bed to bench. vol 7. issue 3. 2014-08-14. PMID:25120899. |
once the diagnosis of cannabinoid hyperemesis was established, he was advised to abstain from cannabis use resulting in complete resolution of his symptoms. |
2014-08-14 |
2023-08-13 |
Not clear |
| Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J Robson, Brian G Rohrback, Elizabeth Thiele, Benjamin Whalley, Daniel Friedma. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. vol 55. issue 6. 2014-08-13. PMID:24854329. |
to present a summary of current scientific evidence about the cannabinoid, cannabidiol (cbd) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. |
2014-08-13 |
2023-08-13 |
human |
| Joseph Habboushe, Jennifer Sedo. Cannabinoid hyperemesis acute renal failure: a common sequela of cannabinoid hyperemesis syndrome. The American journal of emergency medicine. vol 32. issue 6. 2014-08-04. PMID:24418446. |
cannabinoid hyperemesis syndrome (chs) is a recently described condition affecting long-term marijuana users. |
2014-08-04 |
2023-08-12 |
Not clear |
| Yasmin L Hurd, Michael Michaelides, Michael L Miller, Didier Jutras-Aswa. Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology. vol 76 Pt B. 2014-07-29. PMID:23954491. |
we provide an overview of the endocannabinoid system in relation to adolescent cannabis exposure and provide insights regarding factors such as genetics and behavioral traits that confer risk for subsequent addiction. |
2014-07-29 |
2023-08-12 |
Not clear |
| Eman Ilayan, Monika Feliszek, Barbara Malinowska, Eberhard Schlicke. Do cannabinoids exhibit a tyramine-like effect? Naunyn-Schmiedeberg's archives of pharmacology. vol 386. issue 12. 2014-07-15. PMID:23900610. |
the study was extended to another phytocannabinoid, cannabidiol, to the synthetic cannabinoids cp 55,940 and win 55,212-2 and to the endocannabinoids anandamide and 2-arachidonoyl glycerol. |
2014-07-15 |
2023-08-12 |
mouse |
| Eman Ilayan, Monika Feliszek, Barbara Malinowska, Eberhard Schlicke. Do cannabinoids exhibit a tyramine-like effect? Naunyn-Schmiedeberg's archives of pharmacology. vol 386. issue 12. 2014-07-15. PMID:23900610. |
in conclusion, the cannabinoids Δ(9)-tetrahydrocannabinol, cannabidiol, cp 55,940, win 55,212-2, anandamide and 2-arachidonoyl glycerol do not possess a tyramine-like effect on noradrenaline release. |
2014-07-15 |
2023-08-12 |
mouse |
| Girish R Chopda, V Kiran Vemuri, Rishi Sharma, Ganesh A Thakur, Alexandros Makriyannis, Carol A Paroni. Diuretic effects of cannabinoid agonists in mice. European journal of pharmacology. vol 721. issue 1-3. 2014-07-15. PMID:24099963. |
these findings suggest that mice may provide a model for understanding the mixed effects of marijuana on urine output, as described in clinical studies, and aid in the development of targeted cannabinoid based therapies for bladder dysfunction. |
2014-07-15 |
2023-08-12 |
mouse |
| Carlo Pozzill. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert review of neurotherapeutics. vol 13. issue 12 Suppl. 2014-07-15. PMID:24289844. |
an innovative method of benefiting from the mode of action of cannabinoids while limiting their drawbacks is to reduce peak plasma levels of 9-delta-tetrahydrocannabinol and counteract psychoactivity with higher than naturally occurring proportions of a second cannabinoid, cannabidiol. |
2014-07-15 |
2023-08-12 |
Not clear |
| Vincenzo Di Marz. Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction. Expert review of neurotherapeutics. vol 11. issue 4 Suppl. 2014-07-10. PMID:21449854. |
sativex(®) (nabiximols, usan name) contains the two main phytocannabinoids from cannabis sativa, tetrahydrocannabinol and cannabidiol in a 1:1 ratio, and it acts as an endocannabinoid system modulator. |
2014-07-10 |
2023-08-12 |
mouse |
| Patrick Vermersc. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert review of neurotherapeutics. vol 11. issue 4 Suppl. 2014-07-10. PMID:21449855. |
sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. |
2014-07-10 |
2023-08-12 |
Not clear |
| Patrick Vermersc. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert review of neurotherapeutics. vol 11. issue 4 Suppl. 2014-07-10. PMID:21449855. |
sativex(®) (nabiximols, usan name) oromucosal spray contains the two main active constituents of cannabis sativa, tetrahydrocannabinol and cannabidiol in a 1:1 molecular ratio, and acts as an endocannabinoid system modulator. |
2014-07-10 |
2023-08-12 |
Not clear |
| Sabatino Maione, Barbara Costa, Vincenzo Di Marz. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. vol 154 Suppl 1. 2014-07-03. PMID:23623250. |
after 4 millennia of more or less documented history of cannabis use, the identification of cannabinoids, and of Δ(9)-tetrahydrocannabinol in particular, occurred only during the early 1960s, and the cloning of cannabinoid cb1 and cb2 receptors, as well as the discovery of endocannabinoids and their metabolic enzymes, in the 1990s. |
2014-07-03 |
2023-08-12 |
Not clear |